3 Questions to Colleen Kamrad - Vice President and General Manager of GSK Switzerland - Interpharma

Split contribution to:

30 June 2022

3 Questions to Colleen Kamrad – Vice President and General Manager of GSK Switzerland

May we ask you to briefly introduce yourself and tell us a little about your current position in your company?

My name is Colleen Kamrad and I am originally from the United States.  I have been with GSK for 10 years and joined as the Vice President and General Manager of Switzerland in January of 2021. 

GSK is a global healthcare company headquartered in London, England.  Our goal is to unite science, technology and talent to get ahead of disease together.  We prevent and treat disease with vaccines, specialty and general medicines.  We focus on science of the immune system, human genetics, and advanced technologies investing in 4 core therapeutic areas and future opportunities to impact health at scale.

What is your main focus in your role as a board member of Interpharma?

I believe our focus needs to continue to remain on the patients.  It is vital that we work with the various players in the healthcare system to ensure patients in Switzerland have rapid and equitable access to innovative medicines. 

I am also interested in how we can contribute to having the best healthcare system in Switzerland and one element of that is the need to improve the health data ecosystem.

In the Interpharma Annual Report 2021, the topic of Sustainable Development Goals was put in the spotlight. What is GSK doing in this area?

At GSK we want to positively impact the health of more than 2.5 billion people over the next ten years. By using our science and technology to address health needs, by making our products affordable and available, by being a modern employer and by being a responsible business. Three examples of our ambition with concrete goals:

  1. Use access strategies to reach 900 million underserved people in developing countries with our products by 2025.
  2. Accelerate our progress on inclusion and diversity, including aspirational targets for female and ethnically diverse representation in senior roles by end 2025, and recognition as a disability confident employer and in LGBT+ indices.
  3. Have a net zero impact on climate and a net positive impact on nature by 2030.
About us

Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.

Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.

Annual report

Information on our key figures and activities in the financial year 2022

read more

Board and Executive Management

Introducing Interpharma

read more

Vision and Mission

More about the tasks and overriding aims of Interpharma

read more


Contact us

read more


Latest information and media contacts for media representatives

read more